Search results for " Dose"

showing 10 items of 593 documents

Effects of risperidone on conditioned avoidance responding in male mice

1998

The effects of risperidone (0.1, 0.5 and 1 mg/kg) on active avoidance behaviour of BALB/C mice were explored in three acquisition sessions and in one subsequent performance session. In the acquisition phase, risperidone-treated animals showed a decrease in avoidances and in crossings in the adaptation period and in the intertrial intervals (ITIs), and an increase in non-responses; intermediate and high doses also decreased defecation. In the performance phase, 0.5 and 1 mg/kg risperidone decreased avoidance responses, crossings in the adaptation period and ITI crossing, which also decreased with 0.1 mg/kg. Moreover, 0.5 mg/kg of risperidone increased escape responses and 1 mg/kg increased n…

MalePharmacologyMice Inbred BALB Cmedicine.medical_specialtyRisperidonebusiness.industryMale miceRisperidoneMicePsychiatry and Mental healthEndocrinologyAvoidance behaviourInternal medicineAvoidance LearningmedicineHigh dosesDecreased defecationAnimalsDefecationbusinessPsychomotor PerformanceAntipsychotic Agentsmedicine.drugBehavioural Pharmacology
researchProduct

Toxicological Profile of Ultrapure 2,2´,3,4,4´,5,5´-Heptachlorbiphenyl (PCB 180) in Adult Rats

2014

PCB 180 is a persistent non-dioxin-like polychlorinated biphenyl (NDL-PCB) abundantly present in food and the environment. Risk characterization of NDL-PCBs is confounded by the presence of highly potent dioxin-like impurities. We used ultrapure PCB 180 to characterize its toxicity profile in a 28-day repeat dose toxicity study in young adult rats extended to cover endocrine and behavioral effects. Using a loading dose/maintenance dose regimen, groups of 5 males and 5 females were given total doses of 0, 3, 10, 30, 100, 300, 1000 or 1700 mg PCB 180/kg body weight by gavage. Dose-responses were analyzed using benchmark dose modeling based on dose and adipose tissue PCB concentrations. Body w…

MalePhysiologyAdipose tissueTHYROID-HORMONEPOSTNATAL EXPOSURE010501 environmental sciences413 Veterinary scienceToxicologyPathology and Laboratory Medicine01 natural sciencesBiochemistryRats Sprague-DawleyFollicle-stimulating hormoneHemoglobinsMedicine and Health SciencesEFFECT-DIRECTED ANALYSIS0303 health scienceseducation.field_of_studyMultidisciplinaryBehavior AnimalMaintenance doseQRNeurochemistryAnemiaNeurotransmittersHematologyPolychlorinated BiphenylsToxicokineticsAdipose TissueHematocritLiverToxicityBlood ChemistryMedicineEnvironmental PollutantsFemaleLuteinizing hormoneResearch ArticleARYL-HYDROCARBON RECEPTORNeurotoxicologymedicine.medical_specialtyThyroid HormonesPOLYCHLORINATED-BIPHENYLS PCBSScienceeducationPopulationToxic Agentsta3111Loading dose03 medical and health sciencesRetinoidsSex FactorsInternal medicinemedicineSex HormonesDEVELOPMENTAL EXPOSUREAnimalseducationToxic equivalency factorMolecular Biology030304 developmental biology0105 earth and related environmental sciencesToxicityDose-Response Relationship DrugDIBENZO-P-DIOXINSBody WeightBiology and Life SciencesIN-VITROKemiLuteinizing HormoneHormonesRatsDIOXIN-LIKE-PCBSEndocrinologyChemical SciencesAdrenal CortexExploratory BehaviorSUBCHRONIC TOXICITYFollicle Stimulating HormoneDNA Damage
researchProduct

Time Required to Rectify Inhaler Errors Among Experienced Subjects With Faulty Technique

2017

BACKGROUND: Regardless of the device used, many patients have difficulty maintaining proper inhaler technique over time. Repeated education from caregivers is required to ensure persistence of correct inhaler technique, but no information is available to evaluate the time required to rectify inhaler errors in experienced users with a baseline faulty technique and whether this time of re-education to restore inhaler mastery can differ between devices. METHODS: This was a multicenter, single-visit, open-label, cross-sectional study in a large group of 981 adult subjects (mean ± SD age 64 ± 15 y) experienced with inhaler use, mainly suffering from COPD and asthma, who showed faulty inhaler tec…

MalePulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtyTime FactorsTime FactorCross-sectional studyasthma; COPD; inhaler device; Aged; Asthma; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Patient Education as Topic; Pulmonary Disease Chronic Obstructive; Dry Powder Inhalers; Metered Dose Inhalers; Time Factors; Medicine (all)Settore MED/10 - Malattie Dell'Apparato RespiratorioCritical Care and Intensive Care MedicinePulmonary DiseasePulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicinePatient Education as TopicCOPDHumansMedicineMetered Dose Inhalers030212 general & internal medicineAgedAsthmaCross-Sectional StudieCOPDbusiness.industryMedicine (all)InhalerDry Powder InhalersGeneral MedicineMiddle Agedmedicine.diseaseAsthmaDry Powder InhalerCross-Sectional StudiesMetered Dose Inhaler030228 respiratory systemPhysical therapyinhaler deviceFemalebusinessLarge groupHumanRespiratory Care
researchProduct

Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years

2005

Background The minimum age to start specific immunotherapy with inhalant allergens in children has not been clearly established, and position papers discourage its use in children younger than 5 years. Objective To assess the safety of high-dose sublingual-swallow immunotherapy (SLIT) in a group of children younger than 5 years. Methods Sixty-five children (51 boys and 14 girls; age range, 38-80 months; mean ± SD age, 60 ± 10 years; median age, 60 months) were included in this observational study. They were treated with SLIT with a build-up phase of 11 days, culminating in a top dose of 300 IR (index of reactivity) and a maintenance phase of 300 IR 3 times a week. The allergens used were ho…

MalePulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyParietariaImmunologyAdministration SublingualSublingual administrationImmunopathologyAge Factors; Conjunctivitis Allergic; Humans; Allergens; Asthma; Rhinitis; Child; Desensitization Immunologic; Administration Sublingual; Male; Female; Child PreschoolHumansImmunology and AllergyMedicineAge FactorChildRhinitiRhinitisConjunctivitis Allergicbiologybusiness.industryCumulative doseAllergenAge FactorsAllergensbiology.organism_classificationAsthmaDiscontinuationClinical trialEl NiñoDesensitization ImmunologicChild PreschoolFemaleObservational studybusinessHumanAnnals of Allergy, Asthma & Immunology
researchProduct

Patient centring and scan length: how inaccurate practice impacts on radiation dose in CT colonography (CTC).

2019

Objective: The aim of this study was to acknowledge errors in patients positioning in CT colonography (CTC) and their effect in radiation exposure. Materials and methods: CTC studies of a total of 199 patients coming from two different referral hospitals were retrospectively reviewed. Two parameters have been considered for the analysis: patient position in relation to gantry isocentre and scan length related to the area of interest. CTDI vol and DLP were extracted for each patient. In order to evaluate the estimated effective total dose and the dose to various organs, we used the CT-EXPO ® software version 2.2. This software provides estimates of effective dose and doses to the other vario…

MaleRadiology Nuclear Medicine and ImagingSupine positionTime FactorsEstimatedRadiotherapy Setup ErrorsRadiation DosageEffective dose (radiation)Patient Positioning030218 nuclear medicine & medical imagingCentringCohort Studies03 medical and health sciences0302 clinical medicineCT colonography; CTC; estimated; isocentre; positioning; scan length; radiology; nuclear nedicine and imagingnuclear nedicine and imagingCT colonographyProne PositionSupine PositionMedicineHumansIn patientAgedRetrospective StudiesMedical Errorsbusiness.industryUltrasoundRadiation doseAnal orificeScan lengthGeneral MedicineMiddle AgedRadiation ExposureCTCradiologyIsocentre030220 oncology & carcinogenesisTotal doseFemalebusinessNuclear medicineColonography Computed TomographicPositioningLa Radiologia medica
researchProduct

Colonization of adrenal glands and ovaries of mice by HSV-2 variants

1990

HSV-2 strain ER was shown to consist of variants with different pathogenic phenotype: Variant ER+ replicates to high titers in the adrenal glands and the ovaries but much less in the spleen; the testes were not colonized. ER+ migrates to the spinal ganglia and is highly neuroinvasive after i.p. inoculation. Variant ER- replicates 100-1,000 fold less in the adrenal glands and the ovaries, but proceeds to the spinal ganglia without invading the CNS. However, both variants are highly neuropathogenic after direct i.c. injection. We conclude that neuropathogenicity, neuroinvasiveness and the ability to replicate in the adrenal glands as well as ovaries are each determined by different sets of ge…

MaleRatónmedicine.medical_treatmentSpleenOvaryBiologyVirus ReplicationLethal Dose 50MiceSpecies SpecificityVirologyAdrenal GlandsmedicineAnimalsHumansSimplexvirusPropionibacterium acnesVero CellsCells CulturedMice Inbred BALB CAdrenalectomyOvaryAdrenalectomyHerpes SimplexEmbryoGeneral MedicineSilicon DioxideVirologyPhenotypemedicine.anatomical_structureViral replicationVero cellFemaleSpleenArchives of Virology
researchProduct

Mongersen, an oral SMAD7 antisense oligonucleotide, and crohn's disease

2015

Crohn's disease-related inflammation is characterized by reduced activity of the immunosuppressive cytokine transforming growth factor β1 (TGF-β1) due to high levels of SMAD7, an inhibitor of TGF-β1 signaling. Preclinical studies and a phase 1 study have shown that an oral SMAD7 antisense oligonucleotide, mongersen, targets ileal and colonic SMAD7.In a double-blind, placebo-controlled, phase 2 trial, we evaluated the efficacy of mongersen for the treatment of persons with active Crohn's disease. Patients were randomly assigned to receive 10, 40, or 160 mg of mongersen or placebo per day for 2 weeks. The primary outcomes were clinical remission at day 15, defined as a Crohn's Disease Activit…

MaleSMAD7 antisense oligonucleotidemedicine.medical_treatmentOligonucleotidesPharmacologyPLACEBO-CONTROLLED TRIALTHERAPYGastroenterologylaw.inventionACTIVATIONImmunosuppressive AgentGlucocorticoidRandomized controlled trialCrohn DiseaselawOligonucleotideMedicineYoung adultCrohn's diseaseSettore MED/12 - GastroenterologiabiologyINDUCTIONMedicine (all)Remission InductionGeneral MedicineMiddle AgedCrohn's diseaseCytokineC-Reactive ProteinCombinationDrug Therapy CombinationFemaleDrugImmunosuppressive AgentsCOLITISHumanAdultmedicine.medical_specialtyAdolescentINFLAMMATORY-BOWEL-DISEASE PLACEBO-CONTROLLED TRIAL NECROSIS-FACTOR-ALPHA TGF-BETA-1-MEDIATED SUPPRESSION COLITIS INDUCTION ACTIVATION EFFICACY THERAPY MICEPlaceboSmad7 ProteinDose-Response RelationshipYoung AdultPharmacotherapyDouble-Blind MethodDrug TherapyInternal medicineHumansAntisenseGlucocorticoidsAgedDose-Response Relationship Drugbusiness.industryC-reactive proteinNECROSIS-FACTOR-ALPHAOligonucleotides AntisenseTGF-BETA-1-MEDIATED SUPPRESSIONEFFICACYmedicine.diseaseClinical trialMICEbiology.proteinbusinessAdolescent; Adult; Aged; C-Reactive Protein; Crohn Disease; Dose-Response Relationship Drug; Double-Blind Method; Drug Therapy Combination; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Middle Aged; Oligonucleotides; Oligonucleotides Antisense; Remission Induction; Smad7 Protein; Young Adult; Medicine (all)INFLAMMATORY-BOWEL-DISEASE
researchProduct

Oral homeostasis disruption by medical plasticizer component bisphenol A in adult male rats.

2013

Objectives/Hypothesis Bisphenol A (BPA) is a synthetic estrogen-like chemical mimetic widely used in the manufacture of polycarbonate plastics and epoxy resins found in numerous consumer products including food packaging, medical devices, and dental sealants. Because it is recovered in fluids and it can reach high levels in saliva, this study aimed to evaluate its safety on oral homeostasis by examining its effects on salivary glands, mouth epithelium, water consumption, and salt preference, each parameter being estrogen sensitive. Study Design Randomized controlled trial involving rats. Methods A dose-response study was conducted in adult Wistar rats randomized into five groups (n = 12). B…

MaleSalivaBisphenol A[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionMESH : Dose-Response Relationship DrugMESH : DrinkingMESH: PlasticizersMESH: MouthSalivary GlandsThirstMESH: Dose-Response Relationship Drugchemistry.chemical_compoundMESH: Estrogens Non-SteroidalMESH: PhenolsPlasticizersMESH : MouthHomeostasisMESH: Animalssalt preferencemouth drynessSalivary glandMESH : RatsDose–response relationshipmedicine.anatomical_structureMESH : Salivary Glandsendocrine disruptorsthirstMESH: HomeostasisMESH : Homeostasismedicine.symptomMESH : Estrogens Non-SteroidalMESH: DrinkingMESH : Phenolsmedicine.medical_specialtyMESH: Salivary GlandsMESH: Ratsmedicine.drug_classMESH : MaleDrinkingsalivary glandstomatognathic systemPhenolsInternal medicinemedicineMESH: Benzhydryl CompoundsAnimalsMESH: SalivaEstrogens Non-SteroidalBenzhydryl CompoundsSalivaMouthMESH : Benzhydryl CompoundsDose-Response Relationship Drugbusiness.industryBuccal administrationMESH : Disease Models AnimalMESH: MaleRatsDisease Models AnimalEndocrinologyOtorhinolaryngologychemistryEstrogenMESH : PlasticizersMESH : AnimalsMESH : SalivaMESH: Disease Models Animalbusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionHomeostasisThe Laryngoscope
researchProduct

Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabet…

2016

Introduction: Combination therapy is needed to control blood pressure (BP) in a large number of hypertensive patients with diabetes mellitus. Adherence to treatment is a major clinical problem; therefore, the time duration of the antihypertensive action of a drug determines BP control when a dose is skipped. Objectives: The aim was to determine whether the fixed-dose combination of olmesartan/amlodipine provides equal efficacy and safety as the perindopril/amlodipine combination when a drug dose is missed. Methods: In this noninferiority trial with a randomized, double-blind, double-dummy parallel group, controlled design, 260 patients received either olmesartan 20-40 mg/amlodipine 5-10 mg …

MaleSettore MED/09 - Medicina InternaAntihypertensive agentsPhysiologyMissed DoseTetrazolesAngiotensin-Converting Enzyme InhibitorsBlood Pressure030204 cardiovascular system & hematologyPharmacologyEssential hypertensionlaw.invention0302 clinical medicineDiabetes mellitusRandomized controlled triallawAngiotensin II Type 1 Receptor BlockerDrug CombinationPerindoprilMedicine030212 general & internal medicineAntihypertensive agentTetrazoleImidazolesSettore MED/37 - NeuroradiologiaMiddle AgedCalcium Channel BlockersDrug CombinationsTreatment OutcomeHypertensionFemaleEssential HypertensionOlmesartanCalcium Channel BlockerCardiology and Cardiovascular MedicineType 2circulatory and respiratory physiologymedicine.drugHumanAdultmedicine.medical_specialtyAmlodipine; Antihypertensive agents; Blood pressure; Diabetes mellitus; Olmesartan; Perindopril; Internal Medicine; Physiology; Cardiology and Cardiovascular MedicineDiabetes mellitumissed dose; hypertension; therapeutic efficacyCombination therapyUrologytherapeutic efficacyNOMedication Adherence03 medical and health sciencesDouble-Blind MethodInternal MedicineHumansOlmesartanAmlodipineamlodipine antihypertensive agents blood pressure diabetes mellitus olmesartan perindoprilImidazolemissed doseAgedbusiness.industryAngiotensin-Converting Enzyme Inhibitormedicine.diseaseAmlodipine; Antihypertensive agents; Blood pressure; Diabetes mellitus; Olmesartan; Perindopril; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus Type 2; Double-Blind Method; Drug Combinations; Female; Humans; Hypertension; Imidazoles; Male; Medication Adherence; Middle Aged; Perindopril; Tetrazoles; Treatment Outcome; Internal Medicine; Physiology; Cardiology and Cardiovascular MedicineBlood pressureDiabetes Mellitus Type 2PerindoprilAmlodipinebusinessAngiotensin II Type 1 Receptor Blockers
researchProduct

Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine.

2013

Objective Obesity is a mild, long-lasting inflammatory disease and, as such, could increase the inflammatory burden of rheumatoid arthritis (RA). The study aim was to determine whether obesity represents a risk factor for a poor remission rate in RA patients requiring anti–tumor necrosis factor α (anti-TNFα) therapy for progressive and active disease despite treatment with methotrexate or other disease-modifying antirheumatic drugs. Methods Patients were identified from 15 outpatient clinics of university hospitals and hospitals in Italy taking part in the Gruppo Italiano di Studio sulle Early Arthritis network. Disease Activity Score in 28 joints (DAS28), body mass index (BMI; categorized …

MaleSettore MED/16 - REUMATOLOGIAArthritisGastroenterologyReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis RheumatoidRheumatoidMonoclonalReceptorsMedicineOutpatient clinicLongitudinal StudiesRegistriesPrecision Medicineskin and connective tissue diseasesHumanizedRemission InductionAntibodies MonoclonalIndividualized MedicineMiddle AgedTreatment OutcomeRheumatoid arthritisAntirheumatic AgentsFemaleDrugmedicine.drugmusculoskeletal diseasesmedicine.medical_specialtyAdalimumab; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Dose-Response Relationship Drug; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Longitudinal Studies; Male; Middle Aged; Obesity; Precision Medicine; Receptors Tumor Necrosis Factor; Registries; Remission Induction; Treatment Outcome; Tumor Necrosis Factor-alphaAntibodies Monoclonal HumanizedAntibodiesDose-Response RelationshipRheumatologyInternal medicineAdalimumabHumansObesityRisk factorAgedDose-Response Relationship Drugbusiness.industryTumor Necrosis Factor-alphaArthritisAdalimumabmedicine.diseaseInfliximabRheumatologyInfliximabAged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Dose-Response Relationship Drug; Female; Humans; Immunoglobulin G; Individualized Medicine; Longitudinal Studies; Male; Middle Aged; Obesity; Receptors Tumor Necrosis Factor; Registries; Remission Induction; Treatment Outcome; Tumor Necrosis Factor-alphaImmunoglobulin GImmunologybusinessTumor Necrosis FactorArthritis careresearch
researchProduct